Telaprevir inhibits the hepatitis C virus NS3-4A serine protease, leading to the block of viral polyprotein processing. This eventually leads to a decrease of viral RNA replication, HCV RNA levels, as well as and protein levels in the Con1 (genotype 1b) subgenomic HCV replicon cells. This occurs in a time- and dose-dependent manner.